Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | PTGES | O14684 | 11/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | SMO | Q99835 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20489837 | 0.99 | CA1 (0.47) | CA1CA2CA7CA14PTGES | |
| Hydrochloric Acid SCHEMBL29416994 | 0.99 | CA1 (0.47) | CA1CA2CA7CA14PTGES | |
| SCHEMBL18810196 | 0.84 | PTGES (0.56) | CA1CA2CA7CA14PTGES | |
| Hydrochloric Acid SCHEMBL20489802 | 0.83 | PTGES (0.55) | CA1CA2CA7CA14PTGES | |
| Hydrochloric Acid SCHEMBL29417239 | 0.83 | PTGES (0.55) | CA1CA2CA7CA14PTGES | |
| SCHEMBL14966278 | 0.82 | ROCK2 (0.47) | CA1CA2CA7CA14PTGES | |
| SCHEMBL20551918 | 0.81 | HDAC6 (0.46) | CA1CA2CA7CA14PTGES | |
| SCHEMBL18810344 | 0.81 | ERCC1 (0.54) | PTGESSMO | |
| Hydrochloric Acid SCHEMBL20489872 | 0.80 | ERCC1 (0.52) | PTGESSMO | |
| Hydrochloric Acid SCHEMBL29417074 | 0.80 | ERCC1 (0.52) | PTGESSMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3372589-B1 | PYRIMIDINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2021-10-20 | — | — | EP | disclosed |
| US-10710967-B2 | Pyrimidine derivative | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2020-07-14 | — | — | US | disclosed |
| US-20200071280-A1 | PYRIMIDINE DERIVATIVE | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2020-03-05 | — | — | US | disclosed |
| WO-2017073709-A1 | PYRIMIDINE DERIVATIVE | あすか製薬株式会社 | 2017-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071280-A1 | PYRIMIDINE DERIVATIVE | CXCR1, PTGS1, P2RY1 | CA1 3455/4885CA2 2084/4885CA7 4017/4885 |
| US-10710967-B2 | Pyrimidine derivative | CXCR1, PTGS1, P2RY1 | CA1 3455/4885CA2 2084/4885CA7 4017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.